Horizon Therapeutics, LLC   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brisbane CA United States (2006)
Status: Acquired by Amgen (2022)

Organization Overview

First Clinical Trial
2010
NCT01257737
First Marketed Drug
2006
sodium phenylbutyrate (buphenyl)
First NDA Approval
2020
teprotumumab (Tepezza)
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HORIZON THERAP | Horizon Therapeutics | HORIZON THERAPEUTICS IRELAND | Horizon Therapeutics Ireland DAC | HORIZON THERAPEUTICS IRELAND DAC | Horizon Therapeutics, LLC | Horizon Therapeutics USA, Inc. | HORIZON THERAP US